Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at …,

The Company expects to begin a Phase 1 clinical trial in the second quarter of 2021, one quarter earlier than prior guidance. To access the event virtual …, The Company expects to begin a Phase 1 clinical trial in the second quarter of 2021, one quarter earlier than prior guidance. To access the event virtual …, Read More

Scroll to Top